VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 501–600 of 1,000
Melaiu, O., Vanni, G., Portarena, I., Pistolese, C. A., Anemona, L., Pomella, S., Bei, R., Buonomo, O. C., Roselli, M., Mauriello, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043226 · Cited by 27
“VEGF-A has been reported to increase the expression of PD-1, CTLA-4, Tim-3, and Lag3 on CD8+ T cells in a variety of tumors [81].”
BackgroundNanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma
Pan, X., Ni, S., & Hu, K. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122481 · Cited by 30
Tamura, R., Tanaka, T., Morimoto, Y., Kuranari, Y., Yamamoto, Y., Takei, J., Murayama, Y., Yoshida, K., & Sasaki, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.11 · Cited by 27
“Therefore, a combinational approach using anti-VEGF-A and anti-PD-1 antibodies yielded synergistic effects on the CT26 mouse model of colorectal cancer (9).”
BackgroundInfluentialSingh, S. D., Singh, N., Baranwal, M., Sharma, S., Devi, S., & Kumar, S. (2023) · 3 Biotech · doi:10.1007/s13205-023-03826-2 · Cited by 27
“Indole 2,3-dioxygenase (IDO), an enzyme produced by tumour or immune cells, helps in the production and activity of Tregs and myeloid-derived suppressor cells (MDSCs), eventually diminishing T cell effector functionality (Voron et al. 2015; Ngiow et al. 2015).”
BackgroundPhenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
Sun, Y., Yinwang, E., Wang, S., Wang, Z., Wang, F., Xue, Y., Zhang, W., Zhao, S., Mou, H., Chen, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02104-w · Cited by 34
Tamura, R., Morimoto, Y., Sato, M., Kuranari, Y., Oishi, Y., Kosugi, K., Yoshida, K., & Toda, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03388-5 · Cited by 25
Chen, Y., Liu, C., Zhu, S., Liang, X., Zhang, Q., Luo, X., Yuan, L., & Song, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107607 · Cited by 27
Bertol, B. C., Bales, E. S., Calhoun, J., Mayberry, A., Ledezma, M. L., Sams, S. B., Orlicky, D. J., Donadi, E. A., Haugen, B. R., & French, J. D. (2022) · Thyroid · doi:10.1089/thy.2021.0371 · Cited by 26
“We would expect that the T cells in these models would be highly responsive to anti-PD-1 ICBs, which would rescue these cells from activation-induced cell death and early stages of T cell exhaustion (29).”
Zhang, C., Wang, L., Xiong, C., Zhao, R., Liang, H., & Luo, X. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02888-3 · Cited by 30
“The upregulated VEGF expression was also reported to actively participate in tumor escape from immune surveillance by suppressing the proliferation of T-cells and increasing the exhaustion of T-cells [48, 49].”
BackgroundThe metabolic addiction of cancer stem cells
Sahoo, O. S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Alqahtani, M. S., Abbas, M. A. E., Dhar, R., & Karmakar, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955892 · Cited by 26
Brackenier, C., Kinget, L., Cappuyns, S., Verslype, C., Beuselinck, B., & Dekervel, J. (2023) · Cancers · doi:10.3390/cancers15020348 · Cited by 30
Atkins, M. B., Ascierto, P. A., Feltquate, D., Gulley, J. L., Johnson, D. B., Khushalani, N. I., Sosman, J. A., Yap, T. A., Kluger, H. M., Sullivan, R. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005923 · Cited by 30
Zhao, L., Chen, X., Wu, H., He, Q., Ding, L., & Yang, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115724 · Cited by 26
The role of angiogenic growth factors in the immune microenvironment of glioma
Ge, Z., Zhang, Q., Lin, W. J., Jiang, X., & Zhang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1254694 · Cited by 25
Tsukita, Y., Okazaki, T., Ebihara, S., Komatsu, R., Nihei, M., Kobayashi, M., Hirano, T., Sugiura, H., Tamada, T., Tanaka, N., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1543526 · Cited by 26
Self-citationDiminished cytolytic activity of γδ T cells with reduced DNAM-1 expression in neuroblastoma patients
Wang, X., Mou, W., Han, W., Xi, Y., Chen, X., Zhang, H., Qin, H., Wang, H., Ma, X., & Gui, J. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.04.006 · Cited by 25
Liu, C., Li, Z., Wang, S., Fan, Y., Zhang, S., Yang, X., Hou, K., Tong, J., Hu, X., Shi, X., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2761-y · Cited by 24
Weinmann, A., & Galle, P. R. (2020) · Current Oncology · doi:10.3747/co.27.7315 · Cited by 25
Fang, L., Zhao, W., Ye, B., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670313 · Cited by 25
“Moreover, activation of VEGF-VEGFR signaling pathway on CD8+T cells could induce T cell exhaustion and reduce T cell cytotoxicity by increasing the expression of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (40).”
BackgroundCentral Nervous System Metastases
Nieblas‐Bedolla, E., Zuccato, J., Kluger, H. M., Zadeh, G. M., & Brastianos, P. K. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.004 · Cited by 23
Jonasch, E. W., Atkins, M. B., Chowdhury, S., & Mainwaring, P. N. (2022) · Cancers · doi:10.3390/cancers14030644 · Cited by 24
“High levels of circulating VEGF downregulate dendritic cells [30,31] and effector T cells (Figure 1) [32].”
BackgroundTargeting tumor-associated macrophages for cancer immunotherapy
Cao, X., Lai, S. W. T., Chen, S., Wang, S., & Feng, M. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.02.002 · Cited by 28
Merle, P., Blanc, J., Edeline, J., Malicot, K. L., Allaire, M., Assénat, E., Guarssifi, M., Bouattour, M., Péron, J., Laurent‐Puig, P., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.01.161 · Cited by 27
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 28
Muto, H., Kuzuya, T., Kawabe, N., Ohno, E., Funasaka, K., Nagasaka, M., Nakagawa, Y., Miyahara, R., Shibata, T., Hashimoto, S., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16663 · Cited by 26
Cavazzoni, A., Digiacomo, G., Volta, F., Alfieri, R. R., Giovannetti, E., Gnetti, L., Bellini, L., Galetti, M., Fumarola, C., Xu, G., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107438 · Cited by 24
Whipple, C. A., Boni, A., Fisher, J. L., Hampton, T. H., Tsongalis, G. J., Mellinger, D., Yan, S., Tafe, L. J., Brinckerhoff, C., Turk, M. J., et al. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000244 · Cited by 23
Fiedler, U., Ekawardhani, S., Cornelius, A., Gilboy, P., Bakker, T. R., Dolado, I., Stumpp, M. T., & Dawson, K. M. (2017) · Oncotarget · doi:10.18632/oncotarget.21738 · Cited by 28
“The proposed mode-of-action of MP0250 in supporting immunotherapy is: (i) to support T-cell recruitment into the tumor by blocking VEGF and (ii) direct modulation of immune cell functions, including macrophages and dendritic cells [39] [40].”
MethodXipell, M., Victoria, I., Hoffmann, V., Villarreal, J. Z., García‐Herrera, A., Reig, Ò., Rodas, L. M., Blasco, M., Poch, E., Mellado, B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445952 · Cited by 25
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Gao, X. Y., & McDermott, D. F. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000323 · Cited by 23
Nair, D., Rådestad, E., Khalkar, P., Díaz-Argelich, N., Schröder, A., Klynning, C., Ungerstedt, J. S., Uhlin, M., & Fernandes, A. P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00407 · Cited by 23
“Increased levels of vascular endothelial growth factor (VEGF) in the tumor microenvironment have for instance been shown to enhance the expression of PD-1 leading to CD8+ T cell exhaustion (15).”
BackgroundXu, Y., Miller, C. P., Tykodi, S. S., Akilesh, S., & Warren, E. H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1387198 · Cited by 31
Ascierto, P. A., Daniele, B., Hammers, H. J., Hirsh, V., Kim, J. W., Licitra, L. F., Nanda, R., & Pignata, S. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1309-2 · Cited by 22
“Ovarian cancer is known to have an angiogenic phenotype: VEGF has an immune suppressive effect on T cells activation and inversely correlates with TILs infiltration: the association between checkpoint inhibitors and antiangiogenic drugs appears reasonable [78].”
BackgroundCantelmo, A. R., Dejos, C., Kocher, F., Hilbe, W., Wolf, D. G. F., & Pircher, A. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000591 · Cited by 24
Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22
He, S., Tian, S., He, X., Le, X., Ning, Y., Chen, J., Chen, H., Mu, J., Xu, K., Xiang, Q., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.08.008 · Cited by 23
Xue, L., Gao, X., Zhang, H., Tang, J., Wang, Q., Li, F., Li, X., Yu, X., Lu, Z., Huang, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08859-5 · Cited by 23
Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy
Audi, Z. F., Saker, Z., Rizk, M., Harati, H., Fares, Y., Bahmad, H. F., & Nabha, S. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00874-9 · Cited by 23
Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
Sunaga, N., Miura, Y., Kasahara, N., & Sakurai, R. (2021) · Cancers · doi:10.3390/cancers13235956 · Cited by 25
“VEGF prevents dendritic cell development [69] and enhances the coexpression of inhibitory receptors involved in CD8+ T cell exhaustion in tumors, including PD-1 and cytotoxic T-lymphocyte antigen 4 (CTLA-4) [70].”
BackgroundDo Tumor Mechanical Stresses Promote Cancer Immune Escape?
Onwudiwe, K. C., Najera, J., Siri, S., & Datta, M. (2022) · Cells · doi:10.3390/cells11233840 · Cited by 25
“VEGF-A enhances PD-1 expression in VEGFR+CD8+ T cells, thus demonstrating its ability to dampen the anti-tumor immune response [14].”
BackgroundZhao, M., Chen, S., Li, C., Du, Y., & Li, P. (2023) · Cancers · doi:10.3390/cancers15030600 · Cited by 25
An, Y., Pu, N., Jia, J.-B., Wang, W., & Liu, L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188958 · Cited by 26
Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Martin, S. D., Bhuiyan, I., Soleimani, M., & Wang, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154987 · Cited by 28
Iso, H., Hisakane, K., Mikami, E., Suzuki, T., Matsuki, S., Atsumi, K., Nagata, K., Seike, M., & Hirose, T. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-331 · Cited by 28
Acharya, S. S., & Kundu, C. N. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102749 · Cited by 22
Li, B., Li, C., Guo, M., Shang, S., Li, X., Xie, P., Sun, X., Yu, J., & Wang, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171566 · Cited by 22
“Interestingly, VEGF not only promotes angiogenesis but also acts as a key mediator in inhibiting T-cell infiltration and helping tumor cells escape from immune surveillance.(31) Blockage of VEGF was also found to increase T-cell numbers beyond lessened vascularity and then inhibit the tumor growth.”
Zhang, G., Liu, C., Bai, H., Cao, G., Cui, R., & Zhang, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.9902 · Cited by 24
“In addition, VEGF can upregulate other inhibitory receptors, including T‑cell immunoglobulin and mucin domain 3, CTLA‑4 and lymphocyte‑activation gene 3, in a dose‑dependent manner (68).”
Mirando, A. C., Patil, A., Rafie, C. I., Christmas, B. J., Pandey, N. B., Stearns, V., Jaffee, E. M., Torres, E. T. R., & Popel, A. S. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1760685 · Cited by 24
Kim, I.-H., & Lee, H. J. (2022) · Biomedicines · doi:10.3390/biomedicines10020251 · Cited by 23
“Antiangiogenic treatment may promote T-cell priming and activation via dendritic cell maturation [19,20], normalize the tumor vasculature for increased T-cell tumor infiltration [21,22], and establish an immunoreactive tumor microenvironment by decreasing myeloid-derived suppressor cells (MDSCs) and Treg populations […”
BackgroundHuang, Z., Chen, T., Li, W., He, W. A., Liu, S., Wu, Z., Li, B., Yuan, Y., & Qiu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112711 · Cited by 27
Chen, Z., Wu, L., Wang, Q., Yu, Y., Liu, X., Ma, R., Li, T., Li, Y., Song, X., Lin, L., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.10.013 · Cited by 24
Xu, Q., & Shao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487610 · Cited by 27
Eigenbrood, J., Wong, N. W., Mallory, P. W., Pereira, J. S., Williams, D., Morris-II, D. W., Beck, J. A., Cronk, J. C., Sayers, C. M., Mendez, M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3723 · Cited by 27
Immunotherapy in Sarcoma: Future Horizons
Burgess, M. A., Gorantla, V. C., Weiss, K. R., & Tawbi, H. A. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0476-7 · Cited by 22
Calmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Cruz, M. T., Falcão, A. C., & Neves, B. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105309 · Cited by 22
The Impacts of COVID-19 on Musculoskeletal Health
Awosanya, O. D., Dadwal, U. C., Imel, E. A., Yu, Q., & Kacena, M. A. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00734-x · Cited by 22
Amit, M., Xie, T., Gleber‐Netto, F. O., Hunt, P. J., Mehta, G. U., Bell, D., Silverman, D. A., Yaman, I., Ye, Y., Burks, J. K., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02473-4 · Cited by 22
Hu, Y. Y., Paris, S., Bertolet, G., Barsoumian, H. B., Wang, Q., SILVA, J. D., Patel, N. B., Nguyen, N., Doss, D. J., Huang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022011 · Cited by 23
Lazzaro, A., & Hartshorn, K. L. (2023) · Cancers · doi:10.3390/cancers15092506 · Cited by 24
Saux, O. L., Ardin, M., Berthet, J., Ghamry-Barrin, S., Bourhis, M., Cinier, J., Lounici, Y., Treilleux, I., Just, P., Bataillon, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47000-5 · Cited by 24
“Angiogenesis, which is involved in tumorigenesis, tumor growth, and ascites formation in HGSC, has also been associated with immunosuppression through a reduction of effector T cells and an increase in regulatory T cells in the tumor microenvironment 18 – 21 .”
Self-citationLiu, Y., Gong, L., Feng, J. Q., Xiao, C., Liu, C., Chen, B., Chen, L., Jin, M., Guan, Y., Gao, Z., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03170-y · Cited by 28
“VEGF was also found to suppress T cell formation and function and promote T cell depletion by upregulating immune checkpoints [19, 20].”
Tanaka, K., Sugisaka, J., Shiraishi, Y., Watanabe, Y., Daga, H., Azuma, K., Nishino, K., Mori, M., Ota, T., Saito, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58186-7 · Cited by 28
“If the interaction p-value in this adjusted model is still below the cutoff (says, 0.1) then it strength the claim that the VEGF is a predicative biomarker.”
InfluentialTackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
Tabana, Y., Okoye, I., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628138 · Cited by 21
“Checkpoint inhibitors that target PD-1 or CTLA-4 have been used for treating metastatic breast cancer (13).”
BackgroundInfluentialEndothelial cell autophagy in homeostasis and cancer
Verhoeven, J., Baelen, J., Agrawal, M., & Agostinis, P. (2021) · FEBS Letters · doi:10.1002/1873-3468.14087 · Cited by 24
Liu, Y., Zhang, T., Zhang, L., Zhao, C., Zhang, Z., Wang, Z., Gu, M., Li, W., & Li, B. (2022) · Immunotherapy · doi:10.2217/imt-2021-0196 · Cited by 20
Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment
Melo, V. A., Bremer, E., & Martin, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.908389 · Cited by 23
“, 2015) and regulatory T cells are recruited through angiogenic and hypoxia-induced signaling (Facciabene et al., 2011; Voron et al., 2015; Wallin et al., 2016; Palazon et al., 2017).”
BackgroundMeng, T., Han, J., Shi, J., Liao, H., Wen, K., Wang, W., Mui, S., Li, H., Yan, Y., & Xiao, Z. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s411806 · Cited by 24
“Lenvatinib can also control the tumor immune microenvironment by increasing the fraction of activated CD8 T cells while decreasing the proportion of myeloid-derived suppressor cells (MDSCs) and other negative-regulatory immune cells.(8,22,23) Lenvatinib is taken orally and is metabolized by the liver.”
BackgroundPX-478, an HIF-1α inhibitor, impairs mesoCAR T cell antitumor function in cervical cancer
Meymandi, A. R. P., Akbari, B., Soltantoyeh, T., Shahosseini, Z., Hosseini, M., Hadjati, J., & Mirzaei, H. R. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357801 · Cited by 25
“This aligns with previous studies that have shown that the expression of TIM-3, a marker of terminally exhausted T cells, is substantially up-regulated under hypoxic conditions (43, 48, 49).”
ResultImproved Immunotherapy Efficacy by Vascular Modulation
Newport, E., Pedrosa, A., Njegić, A., Hodivala‐Dilke, K., & Muñoz‐Félix, J. M. (2021) · Cancers · doi:10.3390/cancers13205207 · Cited by 21
Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer
Zhang, K., Xu, Y., Chang, X., Xu, C., Xue, W., Ding, D., Nie, M., Cai, H., Xu, J., Zhan, L., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03667-9 · Cited by 22
“Simultane-ously, elevated levels of VEGF and angiogenesis in tumors impede the cytotoxic activity of CD8 + T cells and enhance the presence of immunosuppressive cells, such as regulatory T cells (Treg cells) and M2-like macrophages [61].”
BackgroundLi, T., Ma, W., & Al-Obeidi, E. (2024) · Cancers · doi:10.3390/cancers16132350 · Cited by 21
“The combination of anti-PD-1 antibodies with these agents has demonstrated a strong and synergistic antitumor effect, particularly in tumors that produce high levels of VEGF-A [89].”
BackgroundCombinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 27
Lyu, L., Yi, M., Chen, J., Zhang, J., Ma, X., Zhang, X., Zeng, L., Xue, Y., Wen, H., Deng, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202501819 · Cited by 24
Choucair, K., Radford, M., Bansal, A. K., Park, R., & Saeed, A. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5254 · Cited by 21
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
Kerrison, W. G. J., Lee, A. T. J., Thway, K., Jones, R. L., & Huang, P. H. (2022) · Biomedicines · doi:10.3390/biomedicines10030573 · Cited by 20
Fan, T., Li, S., Li, K., Xu, J., Zhao, S., Li, J., Zhou, X., & Jiang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857715 · Cited by 19
Li, L., Wen, Q., & Ding, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905520 · Cited by 29
“demonstrated that VEGF produced in TME can enhance the expression of PD-1 and other checkpoints involving in CD8 T cell exhaustion (22).”
BackgroundAn, C., Fu, Y., Li, W., Zuo, M., & Wu, P. (2023) · Cancer · doi:10.1002/cncr.34764 · Cited by 21
“Several active intrinsic immune evasion pathways, including overexpression of vascular endothelial growth factor (VEGF), have been confirmed as being linked to HCC progression.(24) Anti‐VEGF agents reduce VEGF‐ mediated immunosuppression and induce blood vessel normalization TAB L E 3 Predictions of time‐dependent end…”
MethodCatalano, M., Procopio, G., Sepe, P., Santoni, M., Sessa, F., Villari, D., Nesi, G., & Roviello, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108499 · Cited by 21
Jiang, N., Zhong, B., Huang, J., Li, W.-C., Zhang, S., Zhu, X., Ni, C., & Shen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1205636 · Cited by 18
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 21
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma
Catalano, M., Gardini, A. C., Vannini, G., Campani, C., Marra, F., Mini, E., & Roviello, G. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1958674 · Cited by 21
“grammed death protein-1 (PD-1) in CD8 + T cells and promotes tumor cell escape [37], one of the main mechanisms of malignant tumorigenesis [38].”
BackgroundRoth, P., Preusser, M., & Weller, M. (2016) · Oncology Research and Treatment · doi:10.1159/000446338 · Cited by 19
Heidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19
“It also increases the proportion of T cells that express PD1, CTLA4, and TIM3 [83].”
Immune checkpoint blockade for cancer therapy: current progress and perspectives
Ye, H., Liao, W., Pan, J., Shi, Y. P., & Wang, Q. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300492 · Cited by 27
“In macrophages, PD-1 expression is upregulated by Toll-like receptor (TLR)-induced NF-κ B activation (Bally et al., 2015; Martinez et al., 2015; Voron et al., 2015).”
Li, W., Xu, M., Cheng, M., Wei, J., Zhu, L., Deng, Y., Guo, F., Bi, F., & Liu, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71065 · Cited by 21
Abikenari, M. A., Sjöholm, M., Liu, J., Nageeb, G., Ha, J. H., Wu, J. Y., Ren, A. L., Sayadi, J. J., Lim, J., Cho, K. B., et al. (2025) · Frontiers in Physics · doi:10.3389/fphy.2025.1723329 · Cited by 20
Wang, X., Wang, J., Wang, Q., Ding, G., Huang, Y., & Feng, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189536 · Cited by 22
The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma
Merle, P. (2021) · Cancers · doi:10.3390/cancers13020238 · Cited by 22
Immune checkpoint blockade in renal cell carcinoma
Rappold, P. M., Silagy, A. W., Kotecha, R. R., & Hakimi, A. A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26339 · Cited by 21
The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention
Zhang, Y., Campbell, B. K., Stylli, S. S., Corcoran, N. M., & Hovens, C. M. (2022) · Uro · doi:10.3390/uro2020010 · Cited by 25
Xu, Y.-J., Zhang, P., Hu, J., Liang, H., Zhu, Y., Cui, Y., Niu, P., Xu, M., & Liu, M. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i4.920 · Cited by 18
Kuwano, A., Yada, M., Narutomi, F., Nagasawa, S., Tanaka, K., Kurosaka, K., Ohishi, Y., Masumoto, A., & Motomura, K. (2022) · Oncology Letters · doi:10.3892/ol.2022.13337 · Cited by 20
Gastric Cancer and the Immune System: The Key to Improving Outcomes?
Keshavjee, S., Moy, R. H., Reiner, S. L., Ryeom, S. W., & Yoon, S. S. (2022) · Cancers · doi:10.3390/cancers14235940 · Cited by 20
“In addition to promoting tumor growth via formation of vasculature, VEGF-A has also been shown to promote an immunosuppressive TME via upregulation of Tregs, promotion of M2 TAM [68], and enhancement CTLA-4 and PD-1 signaling for suppression of CD8+ T cells in murine models [69].”
BackgroundTackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints
Dulal, D., Boring, A. R., Terrero, D., Johnson, T. L., Tiwari, A. K., & Raman, D. (2023) · Cancers · doi:10.3390/cancers15102774 · Cited by 23
Yang, Y., Tang, H. J., Mai, C., Zhang, X., Kuang, J., & Tang, Y. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230601113529 · Cited by 19
Li, X., Ding, X., Liu, M., Wang, J., Sun, W., Teng, Y., Xu, Y., Wu, H., Li, W., Zhou, L., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6302 · Cited by 18
Yang, L., Li, Z., Ye, Z., Li, L., Guan, J., & Gong, W. (2023) · iScience · doi:10.1016/j.isci.2023.107881 · Cited by 20
Liu, Y., Feng, M., Chen, H., Yang, G., Qiu, J., Zhao, F., Cao, Z., Luo, W., Xiao, J., You, L., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.003 · Cited by 18
Lee, Y. J., Lee, J. B., Ha, S., & Kim, H. R. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0044 · Cited by 19
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.